Sugi Predict

Sugi Predict / Compounds / SCHEMBL7023795

SCHEMBL7023795

SCHEMBL7023795

COC(=O)CN(C)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA14 Q9ULX7 4/20 0.39
▸ CA12 O43570 4/20 0.39
▸ CA2 P00918 3/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ CA1 P00915 3/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TSHR P16473 3/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33
▸ CTSD P07339 1/20 0.33
▸ CTSL P07711 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21071237 0.93 KDM4E (0.37) CA14CA12CA2DGAT1CA1
SCHEMBL21070174 0.93 KDM4E (0.37) CA14CA12CA2DGAT1CA1
SCHEMBL1689401 0.88 HDAC6 (0.37) CA14CA12CA2DGAT1CA1
SCHEMBL31485763 0.87 CA14 (0.36) CA14CA12CA2DGAT1CA1
SCHEMBL18112577 0.87 CA14 (0.36) CA14CA12CA2DGAT1CA1
SCHEMBL3187773 0.86 HDAC6 (0.36) CA14CA12CA2DGAT1CA1
SCHEMBL13824284 0.84 DGAT1 (0.38) CA14CA12CA2DGAT1CA1
SCHEMBL14789144 0.84 HDAC6 (0.35) CA14CA12CA2CA1HDAC6
SCHEMBL2589264 0.84 RECQL (0.46) CA14CA12CA2DGAT1CA1
SCHEMBL1925237 0.82 HDAC6 (0.34) CA14CA12CA2CA1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025097104-A1 THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER PGI DRUG DISCOVERY LLC (US) 2025-05-08 — — WO disclosed
EP-4472978-A1 CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION Glenmark Life Sciences Limited (IN) 2024-12-11 — — EP disclosed
CN-117813302-A Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators 沃泰克斯药物股份有限公司 2024-04-02 — — CN disclosed
WO-2023148544-A1 CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION GLENMARK LIFE SCIENCES LIMITED (IN) 2023-08-10 — — WO disclosed
US-20230167082-A1 PRODRUGS IN THE MODULATION OF INTERLEUKIN BRISTOL-MYERS SQUIBB COMPANY 2023-06-01 — — US disclosed
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 — — US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 — — US disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
EP-4134098-A1 METHOD OF CANCER THERAPY ONO Pharmaceutical Co., Ltd. (JP) 2023-02-15 — — EP disclosed
EP-0739886-A2 Selective thrombin inhibitors LG Chemical Limited (KR) 1996-10-30 — — EP disclosed
US-5556909-A PROTEOLYTIC ENZYME INHIBITOR, TREATMENT OF DEGENERATIVE DISEASES, SUCH AS EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS SANOFI WINTHROP INC. (US) 1996-09-17 — — US disclosed
US-5541168-A PROTEOLYTIC ENZYME INHIBITORS; DEGENERATIVE DISEASES; RESPIRATORY, SKIN, GENETIC AND GASTROINTESTINAL DISORDERS; ANTIARRTHRITIC AND -INFLAMMATORY AGENTS; GENETIC DISEASES STERLING WINTHROP INC. (US) 1996-07-30 — — US disclosed
WO-1996016654-A1 2-(2,3,5,6-TETRAFLUORO-4-PYRIDYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 — — WO disclosed
WO-1996016649-A1 2-HETEROCYCLYLOXY AND THIOMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 — — WO disclosed
WO-1996016952-A1 2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 — — WO disclosed
WO-1996016951-A1 SUBSTITUTED 2-ARYLCARBONYLOXYMETHYL-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 — — WO disclosed
WO-1996016970-A1 SUBSTITUTED 2-(PHOSPHINYLOXYMETHYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDES AND COMPOSITIONS AND METHOD OF USE THEREOF SANOFI WINTHROP, INC. (US) 1996-06-06 — — WO disclosed
US-5512576-A TREATMENT OF DEGENERATIVE DISEASES STERLING WINTHROP INC. (US) 1996-04-30 — — US disclosed
US-5494925-A TREATING DEGENERATIVE DISORDERS; PROTEOLYTIC ENZYME INHIBITOR STERLING WINTHROP INC. (US) 1996-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141284-A1 CANCER THERAPEUTIC METHOD STING1, CGAS, IFNAR1 CA14 2204/4885CA12 3162/4885CA2 3284/4885
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC CA14 4495/4885CA12 4688/4885CA2 4501/4885
US-20230151024-A1 STING AGONISTIC COMPOUND STING1, CGAS, TLR1 CA14 4614/4885CA12 4633/4885CA2 3362/4885
US-20230167082-A1 PRODRUGS IN THE MODULATION OF INTERLEUKIN TYK2, IL2, IRAK2 CA14 3683/4885CA12 1810/4885CA2 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.